diarylquinoline drug active atp synthase mycobacterium tuberculosis 
incidence tuberculosis increasing substantially worldwide basis past decade tuberculosis-specific drugs discovered years identified diarylquinoline r207910 potently inhibits drug-sensitive drug-resistant mycobacterium tuberculosis vitro minimum inhibitory concentration mug/ml mice r207910 exceeded bactericidal activities isoniazid rifampin least log unit substitution drugs included world health organizations first-line tuberculosis treatment regimen rifampin isoniazid pyrazinamide r207910 accelerated bactericidal activity leading complete culture conversion months treatment combinations single dose r207910 inhibited mycobacterial growth week plasma levels associated efficacy mice well tolerated healthy human volunteers mutants selected vitro suggest drug targets proton pump adenosine triphosphate atp synthase 
